Compare · ABT vs ABVX
ABT vs ABVX
Side-by-side comparison of Abbott Laboratories (ABT) and Abivax SA (ABVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ABVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.84B, about 20.4x ABVX ($7.73B).
- Over the past year, ABT is down 31.7% and ABVX is up 1594.6% - ABVX leads by 1626.3 points.
- ABT has been more active in the news (7 items in the past 4 weeks vs 5 for ABVX).
- ABT has more recent analyst coverage (25 ratings vs 16 for ABVX).
- Company
- Abbott Laboratories
- Abivax SA
- Price
- $90.39-0.26%
- $102.78+5.41%
- Market cap
- $157.84B
- $7.73B
- 1M return
- +2.83%
- -9.47%
- 1Y return
- -31.70%
- +1594.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 16
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest ABVX
- Abivax SA downgraded by Jefferies with a new price target
- Abivax SA upgraded by Wedbush with a new price target
- SEC Form 6-K filed by Abivax SA
- Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- SEC Form 6-K filed by Abivax SA
- Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
- SEC Form 6-K filed by Abivax SA
- Abivax Announces Results of its May 11, 2026 Annual General Meeting
- Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA